stoxline Quote Chart Rank Option Currency Glossary
ACADIA Pharmaceuticals Inc. (ACAD)
18.19  0.06 (0.33%)    07-23 16:00
Open: 18.01
High: 18.44
Volume: 969,223
Pre. Close: 18.13
Low: 18.01
Market Cap: 3,005(M)
Technical analysis
2024-07-23 4:50:11 PM
Short term     
Mid term     
Targets 6-month :  22.11 1-year :  25.82
Resists First :  18.93 Second :  22.11
Pivot price 17.37
Supports First :  16.26 Second :  14.6
MAs MA(5) :  18.08 MA(20) :  17.01
MA(100) :  17.23 MA(250) :  22.28
MACD MACD :  0.6 Signal :  0.5
%K %D K(14,3) :  74.3 D(3) :  73.8
RSI RSI(14): 66
52-week High :  32.59 Low :  14.55
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ACAD ] has closed below upper band by 28.3%. Bollinger Bands are 22.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 18.47 - 18.56 18.56 - 18.64
Low: 17.79 - 17.89 17.89 - 17.99
Close: 18.02 - 18.19 18.19 - 18.34
Company Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Headline News

Tue, 23 Jul 2024
ProShare Advisors LLC Has $621,000 Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Mon, 22 Jul 2024
Swiss National Bank Raises Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World

Sat, 20 Jul 2024
M&G Plc Invests $5.62 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - MarketBeat

Sun, 14 Jul 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives $28.71 Average Price Target from Brokerages - American Banking and Market News

Fri, 12 Jul 2024
A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals - Markets Insider

Thu, 27 Jun 2024
We Might See A Profit From ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Soon - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 165 (M)
Shares Float 108 (M)
Held by Insiders 0.5 (%)
Held by Institutions 100.9 (%)
Shares Short 11,930 (K)
Shares Short P.Month 12,140 (K)
Stock Financials
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.8
Profit Margin -0.3 %
Operating Margin 7.3 %
Return on Assets (ttm) -0.4 %
Return on Equity (ttm) -0.5 %
Qtrly Rev. Growth 73.8 %
Gross Profit (p.s.) 0
Sales Per Share 4.92
EBITDA (p.s.) 0.03
Qtrly Earnings Growth 0 %
Operating Cash Flow 64 (M)
Levered Free Cash Flow 34 (M)
Stock Valuations
PE Ratio 0
PEG Ratio -0.1
Price to Book value 6.47
Price to Sales 3.69
Price to Cash Flow 47.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android